Author

A. Ilsley

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 3 Biophysics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 4 Assay:proteomics· 4 Organism:human· 3 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Organism:virus· 1

Frequent Co-Authors

A. S. Morgunov· 4 shared S. Fiedler· 4 shared S. R. A. Devenish· 4 shared T. P. J. Knowles· 4 shared A. Aguzzi· 3 shared A. Y. Malik· 3 shared G. Meisl· 3 shared H. Fiegler· 3 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersBiochemistry

A. S. Morgunov

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Serological fingerprints link antiviral activity of therapeutic antibodies to affinity and concentration

S. Fiedler, S. R. A. Devenish, A. S. Morgunov, A. Ilsley, F. Ricci, M. Emmenegger, V. Kosmoliaptsis, E. S. Theel, J. R. Mills, A. M. Sholukh, A. A. A. Aguzzi, A. Iwasaki, A. K. Lynn, T. P. J. Knowles

The paper links antiviral activity of therapeutic antibodies to their affinity and concentration by comparing them to serological fingerprints in convalescent sera.

bioRxiv · Feb 3, 2022Biochemistry

Understanding the role of memory re-activation and cross-reactivity in the defense against SARS-CoV-2

V. Denninger, C. K. Xu, G. Meisl, A. S. Morgunov, S. Fiedler, A. Ilsley, M. Emmenegger, A. Y. Malik, M. A. Piziorska, M. M. Schneider, S. R. A. Devenish, V. Kosmoliaptsis, A. Aguzzi, H. Fiegler, T. P. J. Knowles

This study uses microfluidic antibody-affinity profiling to assess cross-reactive antibodies against SARS-CoV-2 in convalescent patients and pre-pandemic sera, finding low affinity and concentration against SARS-CoV-2 spike protein.

bioRxiv · Jul 23, 2021 · PreprintBiophysics

Mutations in two SARS-CoV-2 variants of concern reflect two distinct strategies of antibody escape

S. Fiedler, V. Denninger, A. S. Morgunov, A. Ilsley, R. Worth, G. Meisl, C. K. Xu, M. A. Piziorska, F. Ricci, A. Y. Malik, S. R. A. Devenish, M. M. Schneider, V. Kosmoliaptsis, A. Aguzzi, A. Iwasaki, , T. P. J. Knowles

This study compares antibody escape mechanisms in SARS-CoV-2 alpha and beta variants, finding they use distinct strategies: alpha increases ACE2 binding affinity, while beta alters epitopes to reduce antibody access.

bioRxiv · Jul 23, 2021 · PreprintBiochemistry

In vitro measurements of protein-protein interactions show that antibody affinity governs the inhibition of SARS-CoV-2 spike/ACE2 binding in convalescent serum

S. Fiedler, M. A. Piziorska, V. Denninger, A. S. Morgunov, A. Ilsley, A. Y. Malik, M. M. Schneider, S. R. A. Devenish, G. Meisl, A. Aguzzi, H. Fiegler, T. P. J. Knowles

The paper measures how antibody affinity affects the inhibition of SARS-CoV-2 spike/ACE2 binding in convalescent serum using in vitro assays.

bioRxiv · Dec 20, 2020 · PreprintBiochemistry